Uroxatral
NDC Package 16590-279-30

11-digit billing NDC: 16590027930

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Uroxatral is 1 INDICATIONS AND USAGEUROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. Marketed by Stat Rx Usa, this product is identified by NDC 16590-279 and is authorized under FDA application NDA021287.

Identification & Billing

NDC Package Code
16590-279-30
Package Description
30 TABLET, EXTENDED RELEASE in 1 BOTTLE
Product Code
11-Digit Billing Format
16590027930
RxNorm Crosswalk
  • RxCUI: 861132 - alfuzosin HCl 10 MG 24HR Extended Release Oral Tablet
  • RxCUI: 861132 - 24 HR alfuzosin hydrochloride 10 MG Extended Release Oral Tablet
  • RxCUI: 861132 - alfuzosin hydrochloride 10 MG 24 HR Extended Release Oral Tablet
  • RxCUI: 861134 - Uroxatral 10 MG 24HR Extended Release Oral Tablet
  • RxCUI: 861134 - 24 HR alfuzosin hydrochloride 10 MG Extended Release Oral Tablet [UroXatral]

Clinical Specifications

Proprietary Name
Uroxatral
Dosage Form
-
Usage Information
1 INDICATIONS AND USAGEUROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is not indicated for the treatment of hypertension.2 DOSAGE AND ADMINISTRATIONThe recommended dosage is one 10 mg UROXATRAL (alfuzosin HCl) extended-release tablet once daily. The extent of absorption of Uroxatral is 50% lower under fasting conditions. Therefore, Uroxatral should be taken immediately after the same meal each day. The tablets should not be chewed or crushed.3 DOSAGE FORMS AND STRENGTHSUROXATRAL (alfuzosin HCl) extended-release tablet 10 mg is available as a round, three-layer tablet: one white layer between two yellow layers, debossed with X10.4 CONTRAINDICATIONSUROXATRAL is contraindicated for use in patients with moderate or severe hepatic impairment (Childs-Pugh categories B and C), since alfuzosin blood levels are increased in these patients. [see Clinical Pharmacology (12.3)].UROXATRAL is contraindicated for use with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased. [see Clinical Pharmacology (12.3)].UROXATRAL is contraindicated in patients known to be hypersensitive to alfuzosin hydrochloride or any component of UROXATRAL tablets.

Regulatory & Marketing

Labeler Name
Stat Rx Usa
FDA Application #
NDA021287
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-05-2009
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 16590-279-30 identifies a specific commercial package of 30 tablet, extended release in 1 bottle of Uroxatral, labeled by Stat Rx Usa. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Stat Rx Usa on June 05, 2009. The current certification is valid through December 31, 2017.

How is this Stat Rx Usa product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 16590027930. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
16590-279-30
11-Digit CMS (5-4-2)
16590-0279-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.